Updated:
Lepu Medical Technology (Beijing) Co.
Lepu Medical Technology was founded in 1999 by Hua Pu in Beijing, China.
Lepu Medical Technology (Beijing) Co.
Lepu Medical Technology was founded in 1999 by Hua Pu in Beijing, China. The company went public on the Shenzhen Stock Exchange in 2009 (ticker: 300003) and remains controlled by the founding family. Hua Pu serves as chairman; his son Hua Li serves as vice president. The underlying wealth originates from medical device manufacturing and distribution. The firm holds a diversified portfolio spanning cardiovascular interventional devices (stents, catheters, pacemakers), industrial technology through subsidiaries like Beijing Lepu Precision Medical Technology, and real estate investments. Geographically, Lepu operates across China, the United States (offices in Pasadena and New York), Europe (Paris, Hellerup), and distributes products to over 100 countries. The company has made acquisitions including the 2011 purchase of Beijing Huaqing Medical Equipment and the 2016 acquisition of Cardiologs, a French digital health company, for an undisclosed sum. The firm maintains co-investment relationships with Chinese state-backed funds and international partners. Lepu employs approximately 8,000 people globally. The company operates a medical device manufacturing plant in Beijing, a research center in Pasadena, and a European distribution hub in Hellerup. The firm maintains philanthropic foundations focused on cardiovascular health in rural China. The most recent operational event of note is the 2023 launch of its next-generation drug-eluting stent in China (per public filings). Lepu's structural differentiator is its hybrid identity as a publicly traded company where the founding family retains majority control, allowing it to operate with the capital access of a listed firm while maintaining the long-term orientation and discretion of a family-controlled enterprise. Its global office network—unusual for a Chinese medical device maker—supports both operational expansion and diversified capital deployment across geographies.
General information
Firm type
other
Year founded
1999
AUM
Undisclosed
Location
Region
North America
Country
China
City
Beijing
Corporate office
Beijing, China
Additional offices
Pasadena, California, United States · New York, New York, United States · Shanghai, China · Paris, France · Hellerup, Denmark
Principals
Hua Pu
Founder
Hua Li
Vice President
Sector focus
Frequently asked questions
Who controls investment decisions at Lepu Medical Technology?
Lepu is controlled by the founding Hua family, with Hua Pu serving as chairman. Hua Li, his son, serves as vice president. The company's board of directors approves major capital allocation, including acquisitions and real estate investments. The founding family maintains majority voting control through their shareholding structure (per public filings).
Is Lepu Medical Technology structured as a family office or a publicly traded company?
Lepu is publicly traded on the Shenzhen Stock Exchange (ticker: 300003) but remains family-controlled. It is not a traditional family office; it operates as a publicly listed industrial corporation. The founding family uses the company's balance sheet for capital deployment, which includes both operating business investments and financial holdings across real estate and industrial technology.
What is Lepu's known posture on co-investments and partnerships?
Lepu has engaged in co-investments with Chinese state-backed funds and international partners for acquisitions. The 2016 acquisition of Cardiologs involved co-investment from European venture partners. The firm also collaborates with academic hospitals and research institutions in China, the U.S., and Europe for clinical trials and device development (per public filings and press releases).
Where does the family's wealth originate?
The wealth originates from the medical device industry. Hua Pu founded Lepu Medical in 1999 and built it into a leading Chinese manufacturer of cardiovascular devices. The company's success in stents, catheters, and other interventional products generated substantial equity value, which the founding family has diversified into real estate and industrial holdings.
Does Lepu maintain philanthropic structures?
Yes, Lepu operates philanthropic initiatives focused on cardiovascular health in rural China. These include charitable programs distributing stents and training physicians in underserved regions. The family has not established a separate endowed foundation; charitable activities are conducted through the company's corporate social responsibility arm.
What investment stages and sectors does Lepu typically target?
Lepu targets growth-stage and strategic acquisitions primarily in medical technology, including cardiovascular devices, digital health (Cardiologs), and precision medical equipment. The firm also makes real estate investments and holds industrial technology subsidiaries. The company does not actively target early-stage venture investments or pure financial assets; its investments are predominantly strategic and operational.
Is Lepu's capital deployment purely internal or does it make fund commitments?
Lepu's capital deployment is primarily direct—through acquisitions, R&D investment, and real estate holdings. The firm does not publicly report allocations to external fund managers. Co-investments with state-backed funds and international partners occur on a deal-by-deal basis.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: